Kura Oncology Highlights Darlifarnib’s Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy
Kura Oncology presented preliminary Phase 1a data from the FIT-001 study at ASCO, showing darlifarnib plus adagrasib achieved confirmed objective response rates of 67% in pancreatic cancer and 50% in non-small cell lung cancer. The combination also showed a 29% response rate in KRAS inhibitor-naïve colorectal cancer patients, with tumor shrinkage observed in 77% of all evaluable patients and 94% of KRAS inhibitor-naïve patients.
Key figures
- Drug Name
- darlifarnib
- Phase Of Trial
- Phase 1a
- Orr nslc
- 50%
- Orr pdac
- 67%
- Orr crc naive
- 29%
- Tumor shrinkage naive
- 94%
- Tumor shrinkage overall
- 77%
- Response evaluable patients
- 26
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.